疑似NSTE-ACS入院后3个月GDF-15的预后价值
本研究在758例疑似非ST段抬高型急性冠脉综合征(NSTE-ACS)患者中,于入院时和3个月后检测生长分化因子-15(GDF-15),随访中位1540天。结果显示3个月时GDF-15≥1200 pg/mL者全因死亡和复合终点发生率显著更高,且GDF-15浓度与全因死亡和复合终点独立相关,GDF-15变化也可提供预后信息。
要点
- 疑似NSTE-ACS入院后3个月GDF-15≥1200 pg/mL者全因死亡18%、复合终点25%。
- 3个月GDF-15(log2转换)与全因死亡独立相关(调整HR 2.2)。
- GDF-15从基线到3个月变化10%与全因死亡风险增加相关(HR 1.06)。
核心结论
- 疑似NSTE-ACS入院后3个月高GDF-15浓度与长期死亡和心血管事件相关,独立于传统危险因素和肌钙蛋白T。
- GDF-15浓度变化可提供预后信息。
研究设计与样本
- 在758例因疑似NSTE-ACS入院的患者中,于基线及入院后3个月检测GDF-15。
- 3个月访视后随访中位1540天(IQR:1087-1776天)。
- 主要终点为全因死亡,次要复合终点包括全因死亡、新发心肌梗死和心力衰竭住院。
主要发现
- GDF-15≥1200 pg/mL组(n=248)中18%死亡、25%达到复合终点。
- GDF-15<1200 pg/mL组(n=510)中1.7%死亡、4%达到复合终点。
- 3个月GDF-15(log2转换)与全因死亡独立相关(调整HR:2.2,95% CI:1.4至3.3,p<0.001)。
- 3个月GDF-15(log2转换)与复合终点独立相关(调整HR:1.9,95% CI:1.4至2.7,p<0.001)。
- GDF-15从基线到3个月变化10%与全因死亡风险增加相关(HR:1.06,95% CI:1.01至1.13,p=0.031),调整基线GDF-15浓度。
临床怎么用
- 对疑似NSTE-ACS入院患者,可考虑在3个月时检测GDF-15以辅助长期风险分层。
- GDF-15≥1200 pg/mL提示长期死亡和心血管事件风险较高。
- GDF-15从基线到3个月的变化可提供额外预后信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Growth differentiation factor-15 (GDF-15) is a predictor of death and cardiovascular events when measured during index hospitalisation in patients with acute chest pain. This study investigated the prognostic utility of measuring GDF-15 3 months after an admission with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: GDF-15 was measured at baseline and 3 months after admission in 758 patients admitted with suspected NSTE-ACS. Patients were followed for a median of 1540 (IQR: 1087-1776) days after the 3-month visit. The primary endpoint was all-cause mortality, while the secondary composite endpoint included all-cause mortality, incident myocardial infarction and heart failure hospitalisation during follow-up. RESULTS: In patients with GDF-15 ≥1200 pg/mL (n=248), 18% died and 25% met the composite endpoint. In patients with GDF-15 <1200 pg/mL (n=510), 1.7% died and 4% met the composite endpoint. The GDF-15 concentration (log2 transformed) at 3 months was significantly associated with all-cause mortality (adjusted HR: 2.2, 95% CI: 1.4 to 3.3, p<0.001) and the composite endpoint (adjusted HR: 1.9, 95% CI: 1.4 to 2.7, p<0.001), independently of traditional risk factors and baseline troponin T. A 10% change in GDF-15 concentration from baseline to the 3-month visit was associated with increased risk of all-cause mortality (HR: 1.06, 95% CI: 1.01 to 1.13, p=0.031), adjusting for baseline GDF-15 concentrations. CONCLUSIONS: High GDF-15 concentrations 3 months after admission for suspected NSTE-ACS are associated with long-term mortality and cardiovascular events, independent of traditional risk factors and troponin T. A change in GDF-15 concentration can provide prognostic information.
引用
- Myrmel, Steiro, Tjora, et al. Prognostic value of growth differentiation factor-15 3 months after an acute chest pain admission. Heart. 2024. PMID: 38000899. doi:10.1136/heartjnl-2023-323260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。